Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2017

01-04-2017 | Original Article

The Burdens, Concerns, and Quality of Life of Patients with Gastroparesis

Authors: Daohai Yu, Frederick V. Ramsey, William F. Norton, Nancy Norton, Susan Schneck, Tegan Gaetano, Henry P. Parkman

Published in: Digestive Diseases and Sciences | Issue 4/2017

Login to get access

Abstract

Aims

The impact of gastroparesis on patients from the patient’s viewpoint is needed to better address treatment priorities. The aims of this study were to: (1) Delineate burdens and concerns of patients with gastroparesis; (2) investigate specific symptoms contributing to impaired quality of life (QOL) in gastroparesis.

Methods

The International Foundation for Functional GI Disorders gastroparesis survey questionnaire was developed to describe patients’ viewpoint about their experience with gastroparesis and included Patient Assessment of Upper GI Symptoms (PAGI-SYM) and SF-36 QOL survey.

Results

A total of 1423 adult patients with gastroparesis completed the survey. Average duration of gastroparesis symptoms was 9.3 years with time from onset to diagnosis 5.0 years. Patients felt that they receive good information regarding treatment options from physicians, the Internet, and Facebook. Patients rated their satisfaction with available treatment for their gastroparesis as dissatisfied (33%), somewhat dissatisfied (27%), neutral (14%), somewhat satisfied (15%), and satisfied (4%). Patients felt that gastroparesis symptoms that are most important to improve with treatment are nausea, stomach pain, and vomiting. Overall, there was a decreased quality of life by SF-36. Physical health QOL score was negatively correlated with symptoms including nausea (r = −0.37), upper abdominal pain (r = −0.37), and early satiety (r = −0.37).

Conclusions

This large series of patients with gastroparesis describes their burdens, concerns, and QOL. Nausea, vomiting, early satiety, and abdominal pain are important symptoms for treatment. Many patients are not satisfied with current treatments, wanting specific treatments for their disorder. Interestingly, a large number of patients find out about treatments, not only from their physician, but also using the Internet including social media.
Literature
1.
go back to reference Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998;43:2398–2404.CrossRefPubMed Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998;43:2398–2404.CrossRefPubMed
2.
go back to reference Harrell SP, Studts JL, Dryden GW, Eversmann J, Cai L, Wo JM. A novel classification scheme for gastroparesis based on predominant-symptom presentation. J Clin Gastroenterol. 2008;42:455–459.CrossRefPubMed Harrell SP, Studts JL, Dryden GW, Eversmann J, Cai L, Wo JM. A novel classification scheme for gastroparesis based on predominant-symptom presentation. J Clin Gastroenterol. 2008;42:455–459.CrossRefPubMed
3.
go back to reference Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol. 2011;9:1056–1064.CrossRefPubMed Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol. 2011;9:1056–1064.CrossRefPubMed
4.
go back to reference Pasricha PJ, Yates KP, Nguyen L, et al. Outcomes and factors associated with reduced symptoms in patients with gastroparesis. Gastroenterology. 2015;149:1762–1774.CrossRefPubMedPubMedCentral Pasricha PJ, Yates KP, Nguyen L, et al. Outcomes and factors associated with reduced symptoms in patients with gastroparesis. Gastroenterology. 2015;149:1762–1774.CrossRefPubMedPubMedCentral
5.
go back to reference Farup CE, Leidy NK, Murray M, Williams GR, Helbers L, Quigley EM. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care. 1998;21:1699–1706.CrossRefPubMed Farup CE, Leidy NK, Murray M, Williams GR, Helbers L, Quigley EM. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care. 1998;21:1699–1706.CrossRefPubMed
6.
go back to reference DiBaise JK, Patel N, Noelting J, Dueck AC, Roarke M, Crowell MD. The relationship among gastroparetic symptoms, quality of life, and gastric emptying in patients referred for gastric emptying testing. Neurogastroenterol Motil. 2016;28:234–242.CrossRefPubMed DiBaise JK, Patel N, Noelting J, Dueck AC, Roarke M, Crowell MD. The relationship among gastroparetic symptoms, quality of life, and gastric emptying in patients referred for gastric emptying testing. Neurogastroenterol Motil. 2016;28:234–242.CrossRefPubMed
7.
go back to reference Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13:1737–1744.CrossRefPubMed Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13:1737–1744.CrossRefPubMed
8.
go back to reference Ware JE, Kosinski M, Dewey JE. How to score version 2 of the SF-36 ® health survey. Lincoln, RI: QualityMetric Incorporated; 2000. Ware JE, Kosinski M, Dewey JE. How to score version 2 of the SF-36 ® health survey. Lincoln, RI: QualityMetric Incorporated; 2000.
9.
go back to reference Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43:541–550.CrossRefPubMedPubMedCentral Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43:541–550.CrossRefPubMedPubMedCentral
10.
go back to reference Revicki DA, Rentz AM, Dubois D, et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther. 2003;18:141–150.CrossRefPubMed Revicki DA, Rentz AM, Dubois D, et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther. 2003;18:141–150.CrossRefPubMed
11.
go back to reference Ware JE, Kosinski M. SF-36 ® physical and mental health summary scales: a manual for users of version 1. 2nd ed. Lincoln, RI: QualityMetric Inc; 2001. Ware JE, Kosinski M. SF-36 ® physical and mental health summary scales: a manual for users of version 1. 2nd ed. Lincoln, RI: QualityMetric Inc; 2001.
12.
go back to reference Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33:350–357.CrossRefPubMed Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33:350–357.CrossRefPubMed
13.
go back to reference Hays RD, Sherbourne CD, Spritzer KL, Dixon WJ. A microcomputer program (sf36.exe) that generates SAS Code for scoring the SF-36 health survey. In: Proceedings of the 22nd Annual SAS Users Group International Conference; 1996:1128–1132. Hays RD, Sherbourne CD, Spritzer KL, Dixon WJ. A microcomputer program (sf36.exe) that generates SAS Code for scoring the SF-36 health survey. In: Proceedings of the 22nd Annual SAS Users Group International Conference; 1996:1128–1132.
14.
go back to reference Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 ® health survey manual and interpretation guide. Boston, MA: New England Medical Center, The Health Institute; 1993. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 ® health survey manual and interpretation guide. Boston, MA: New England Medical Center, The Health Institute; 1993.
15.
go back to reference Revicki DA, Camilleri M, Kuo B, Szarka LA, McCormack J, Parkman HP. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD). Neurogastroenterol Motil. 2012;24:456–463.CrossRefPubMed Revicki DA, Camilleri M, Kuo B, Szarka LA, McCormack J, Parkman HP. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD). Neurogastroenterol Motil. 2012;24:456–463.CrossRefPubMed
16.
go back to reference Hui R. Gastroparesis: Clinical Evaluation of Drugs for Treatment: Guidance for Industry. Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2015. Hui R. Gastroparesis: Clinical Evaluation of Drugs for Treatment: Guidance for Industry. Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2015.
17.
go back to reference Jung H, Choung RS, Locke GR III, et al. The incidence, prevalence, and outcomes of patients with gastroparesis, in Olmsted County, Minnesota, from 1996–2006. Gastroenterology. 2009;136:1225–1233.CrossRefPubMed Jung H, Choung RS, Locke GR III, et al. The incidence, prevalence, and outcomes of patients with gastroparesis, in Olmsted County, Minnesota, from 1996–2006. Gastroenterology. 2009;136:1225–1233.CrossRefPubMed
18.
go back to reference Rey E, Choung RS, Schleck CD, Zinsmeister AR, Talley NJ, Locke GR III. Prevalence of hidden gastroparesis in the community: the gastroparesis “iceberg”. J Neurogastroenterol Motil. 2012;18:34–42.CrossRefPubMedPubMedCentral Rey E, Choung RS, Schleck CD, Zinsmeister AR, Talley NJ, Locke GR III. Prevalence of hidden gastroparesis in the community: the gastroparesis “iceberg”. J Neurogastroenterol Motil. 2012;18:34–42.CrossRefPubMedPubMedCentral
19.
go back to reference Choung RS, Locke GR III, Schleck CD, Zinsmeister AR, Melton LJ, Talley NJ. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol. 2012;107:82–88.CrossRefPubMed Choung RS, Locke GR III, Schleck CD, Zinsmeister AR, Melton LJ, Talley NJ. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol. 2012;107:82–88.CrossRefPubMed
20.
go back to reference Jones KL, Russo A, Stevens JE, et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24:1264–1269.CrossRefPubMed Jones KL, Russo A, Stevens JE, et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24:1264–1269.CrossRefPubMed
21.
go back to reference Hasler WL, Parkman HP, Wilson LA, et al. Psychological dysfunction is associated with symptom severity but not disease etiology or degree of gastric retention in patients with gastroparesis. Am J Gastroenterol. 2010;105:2357–2367.CrossRefPubMedPubMedCentral Hasler WL, Parkman HP, Wilson LA, et al. Psychological dysfunction is associated with symptom severity but not disease etiology or degree of gastric retention in patients with gastroparesis. Am J Gastroenterol. 2010;105:2357–2367.CrossRefPubMedPubMedCentral
22.
go back to reference Jones KL, Russo A, Berry MK, et al. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patient with diabetes mellitus. Am J Med. 2002;113:449–455.CrossRefPubMed Jones KL, Russo A, Berry MK, et al. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patient with diabetes mellitus. Am J Med. 2002;113:449–455.CrossRefPubMed
Metadata
Title
The Burdens, Concerns, and Quality of Life of Patients with Gastroparesis
Authors
Daohai Yu
Frederick V. Ramsey
William F. Norton
Nancy Norton
Susan Schneck
Tegan Gaetano
Henry P. Parkman
Publication date
01-04-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4456-7

Other articles of this Issue 4/2017

Digestive Diseases and Sciences 4/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.